{
    "clinical_study": {
        "@rank": "79185", 
        "brief_summary": {
            "textblock": "RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes\n      necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop\n      cancer cells from dividing so they stop growing or die. Combining imatinib mesylate and\n      chemotherapy may kill more cancer cells.\n\n      PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate plus cytarabine in\n      treating patients who have newly diagnosed chronic myeloid leukemia."
        }, 
        "brief_title": "Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia", 
        "condition": "Leukemia", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Myeloid", 
                "Leukemia, Myelogenous, Chronic, BCR-ABL Positive", 
                "Leukemia, Myeloid, Chronic-Phase"
            ]
        }, 
        "detailed_description": {
            "textblock": "OBJECTIVES:\n\n        -  Determine the maximum tolerated dose of imatinib mesylate and cytarabine in patients\n           with newly diagnosed chronic phase chronic myeloid leukemia.\n\n        -  Determine the feasibility of this regimen as defined by dose-limiting toxicity of this\n           regimen and treatment-related mortality in no more than 5% of these patients.\n\n        -  Determine the rate and duration of molecular response, complete hematological response,\n           and complete cytogenetic response in patients treated with this regimen.\n\n        -  Determine the time to treatment failure of patients treated with this regimen.\n\n        -  Determine the overall survival of patients treated with this regimen.\n\n      OUTLINE: This is a multicenter, dose-escalation study of imatinib mesylate and cytarabine.\n\n      Patients receive oral imatinib mesylate alone once daily on days 1-21. Patients then receive\n      oral imatinib mesylate once daily and cytarabine IV over 1-3 hours on days 1-7. Combination\n      therapy repeats every 28-42 days for 2 courses. Patients then receive maintenance oral\n      imatinib mesylate once daily. Treatment continues in the absence of disease progression or\n      unacceptable toxicity.\n\n      Cohorts of 5-20 patients receive escalating doses of imatinib mesylate and cytarabine until\n      the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding\n      that at which at least 5/5, 5/10, or 5/20 patients experience dose-limiting toxicity.\n\n      Patients are followed every 6 months.\n\n      PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study within 2 years."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "DISEASE CHARACTERISTICS:\n\n          -  Newly diagnosed chronic myeloid leukemia in first chronic phase (within the past 6\n             months)\n\n               -  Philadelphia-chromosome positive OR\n\n               -  bcr-abl rearrangement\n\n          -  No prior treatment within the past 6 months other than hydroxyurea\n\n        PATIENT CHARACTERISTICS:\n\n        Age:\n\n          -  18 to 65\n\n        Performance status:\n\n          -  WHO 0-2\n\n        Life expectancy:\n\n          -  Not specified\n\n        Hematopoietic:\n\n          -  Not specified\n\n        Hepatic:\n\n          -  No hepatic dysfunction\n\n          -  Bilirubin less than 2 times normal\n\n          -  ALT less than 4 times normal\n\n        Renal:\n\n          -  No renal dysfunction\n\n          -  Creatinine less than 2.3 mg/dL\n\n        Cardiovascular:\n\n          -  No severe cardiac dysfunction\n\n          -  No New York Heart Association class II-IV heart disease\n\n        Pulmonary:\n\n          -  No severe pulmonary disease\n\n        Other:\n\n          -  HIV negative\n\n          -  No severe neurologic disease\n\n          -  No active uncontrolled infection\n\n          -  No other active malignancy within the past 5 years except basal cell skin cancer or\n             stage 0 cervical cancer\n\n          -  Not pregnant or nursing\n\n        PRIOR CONCURRENT THERAPY:\n\n        Biologic therapy:\n\n          -  See Disease Characteristics\n\n          -  No concurrent allogeneic transplantation with an HLA-A, B, DR-matched sibling donor\n             or matched-unrelated donor\n\n        Chemotherapy:\n\n          -  See Disease Characteristics\n\n        Endocrine therapy:\n\n          -  See Disease Characteristics\n\n        Radiotherapy:\n\n          -  See Disease Characteristics\n\n        Surgery:\n\n          -  See Disease Characteristics\n\n        Other:\n\n          -  No concurrent grapefruit or grapefruit juice"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 4, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00028847", 
            "org_study_id": "CDR0000069141", 
            "secondary_id": [
                "CKTO-2001-03", 
                "HOVON-51CML", 
                "EU-20132", 
                "HOVON-CKTO-2001-03", 
                "NOVARTIS-CST1571ANL01"
            ]
        }, 
        "intervention": [
            {
                "intervention_name": "cytarabine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "imatinib mesylate", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cytarabine", 
                "Imatinib"
            ]
        }, 
        "keyword": [
            "chronic phase chronic myelogenous leukemia", 
            "chronic myelogenous leukemia, BCR-ABL1 positive"
        ], 
        "lastchanged_date": "September 16, 2013", 
        "link": {
            "description": "Clinical trial summary from the National Cancer Institute's PDQ\u00ae database", 
            "url": "http://cancer.gov/clinicaltrials/CKTO-2001-03"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Brugge", 
                        "country": "Belgium", 
                        "zip": "8000"
                    }, 
                    "name": "AZ Sint-Jan"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1200"
                    }, 
                    "name": "Cliniques Universitaires Saint-Luc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussels", 
                        "country": "Belgium", 
                        "zip": "1000"
                    }, 
                    "name": "Institut Jules Bordet"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium", 
                        "zip": "B-3000"
                    }, 
                    "name": "U.Z. Gasthuisberg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Mont-Godinne Yvoir", 
                        "country": "Belgium", 
                        "zip": "5530"
                    }, 
                    "name": "Clinique Universitaire De Mont-Godinne"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "'s-Gravenhage", 
                        "country": "Netherlands", 
                        "zip": "2545 CH"
                    }, 
                    "name": "HagaZiekenhuis - Locatie Leyenburg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amersfoort", 
                        "country": "Netherlands", 
                        "zip": "3816 CP"
                    }, 
                    "name": "Meander Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1105 AZ"
                    }, 
                    "name": "Academisch Medisch Centrum at University of Amsterdam"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "10P 1HV"
                    }, 
                    "name": "Vrije Universiteit Medisch Centrum"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Enschede", 
                        "country": "Netherlands", 
                        "zip": "7500 KA"
                    }, 
                    "name": "Medisch Spectrum Twente"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Groningen", 
                        "country": "Netherlands", 
                        "zip": "9713 EZ"
                    }, 
                    "name": "University Medical Center Groningen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2300 RC"
                    }, 
                    "name": "Leiden University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nijmegen", 
                        "country": "Netherlands", 
                        "zip": "6500 HB"
                    }, 
                    "name": "Universitair Medisch Centrum St. Radboud - Nijmegen"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3008 AE"
                    }, 
                    "name": "Daniel Den Hoed Cancer Center at Erasmus Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584 CX"
                    }, 
                    "name": "University Medical Center Utrecht"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Zwolle", 
                        "country": "Netherlands", 
                        "zip": "8000 GK"
                    }, 
                    "name": "Isala Klinieken - locatie Sophia"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "official_title": "A Dose-ranging Phase I/II Study of STI571 in Combination With Cytarabin in Patients With First Chronic Phase Chronic Myeloid Leukemia", 
        "overall_official": {
            "affiliation": "Daniel Den Hoed Cancer Center at Erasmus Medical Center", 
            "last_name": "J.J. Cornelissen, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_outcome": {
            "measure": "Incidence of dose-limiting toxicity and treatment-related toxicity per dose level", 
            "safety_issue": "Yes"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00028847"
        }, 
        "results_reference": [
            {
                "PMID": "20015886", 
                "citation": "Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, L\u00f6wenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica. 2010 Jun;95(6):914-21. doi: 10.3324/haematol.2009.016766. Epub 2009 Dec 16."
            }, 
            {
                "PMID": "18172005", 
                "citation": "Deenik W, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Kluin-Nelemans HC, Verdonck LF, Ferrant A, Schattenberg AV, Janssen JJ, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Westveer PH, Beverloo HB, Valk P, Lowenberg B, Ossenkoppele GJ, Cornelissen JJ. Dose finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood. 2008 Jan 2; [Epub ahead of print]"
            }
        ], 
        "secondary_outcome": [
            {
                "measure": "Rate and duration of molecular response", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Rate and duration of complete hematological response", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Rate and duration of complete cytogenetic response", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Time to treatment failure", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Commissie Voor Klinisch Toegepast Onderzoek", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2001", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2011"
    }, 
    "geocoordinates": {
        "AZ Sint-Jan": "51.211 3.225", 
        "Academisch Medisch Centrum at University of Amsterdam": "52.37 4.895", 
        "Clinique Universitaire De Mont-Godinne": "50.359 4.882", 
        "Cliniques Universitaires Saint-Luc": "50.85 4.352", 
        "Daniel Den Hoed Cancer Center at Erasmus Medical Center": "51.924 4.482", 
        "HagaZiekenhuis - Locatie Leyenburg": "52.07 4.301", 
        "Institut Jules Bordet": "50.85 4.352", 
        "Isala Klinieken - locatie Sophia": "52.499 6.084", 
        "Leiden University Medical Center": "52.16 4.494", 
        "Meander Medisch Centrum": "52.156 5.388", 
        "Medisch Spectrum Twente": "52.222 6.894", 
        "U.Z. Gasthuisberg": "50.878 4.704", 
        "Universitair Medisch Centrum St. Radboud - Nijmegen": "51.843 5.855", 
        "University Medical Center Groningen": "53.219 6.567", 
        "University Medical Center Utrecht": "52.09 5.11", 
        "Vrije Universiteit Medisch Centrum": "52.37 4.895"
    }
}